Educating FQHC Providers to Advance Pharmacogenomics and Research Participation in Diverse Settings
This program is designed for clinical providers and staff at a federally qualified health center
Objectives Upon completion of this activity, participants will be able to:
1. Recognize the availability of evidence-based guidelines that synthesize information relevant to genomic/pharmacogenomic
tests and selection of drug therapy (eg, clinical pharmacogenomics implementation consortium).
2. Appreciate the potential benefits, limitations, and risks of genetic testing/information for individuals.
3. Understand the influence (or lack thereof) of ethnicity in genetic polymorphisms and associations of polymorphisms with drug
4. Define common terms and nomenclature used in PGx.
5. Compare/contrast different PGx study designs.
6. Learn a step-wise decision-making process for the integration of PGx into clinical practice.
No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients to disclose.
This activity has been approved for AMA PRA Category 1 Credit™
- 4.00 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 4.00 Attendance